|
|
||||||||
1From the L. V. Prasad Eye Institute, Hyderabad, India; and the 2Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India.
| Abstract |
|---|
|
|
|---|
METHODS. DNA samples from 146 patients with PCG from 138 pedigrees were analyzed for several distinct mutations in CYP1B1 by PCR-RFLP.
RESULTS. PCR-RFLP screening revealed that 30.8% of patients were positive for any one of the six mutations (376insA, 528G
A, 923C
T, 959G
A, 1449G
A, and 1514C
A), and 17.8% of the patients were found to have the rarely reported mutation R368H (1449G
A). All mutations were confirmed by DNA sequencing.
CONCLUSIONS. The results suggest extensive allelic heterogeneity in the Indian patients with PCG, with the predominant allele being R368H among the 146 Indian patients tested. It appears possible to use this approach for carrier detection in pedigrees with a positive family history and in population screening. The approach also offers a method for rapid screening of potential carriers and affected individuals.
An autosomal recessive mode of inheritance pattern is well documented for PCG. Even though three different loci have been mapped for PCG5 6 (Stoilov IR, et al. IOVS 2002;43:ARVO E-Abstract 3015), mutations in the CYP1B1 gene (GLC3A locus5 ) is the most predominant7 and is reported in various ethnic backgrounds.7 8 9 10 11 12 13 14 15 16 17 18 19 20 An additional PCG locus, GLC3B,6 has been mapped to the short arm of chromosome 1, region 36, and a third locus, GLC3C (Stoilov IR, et al. IOVS 2002;43:ARVO E-Abstract 3015), to 14q24.3, but the genes have not been identified in these two loci. Recently, we showed the association of CYP1B1 with PCG in the Indian population18 and detected five distinct mutations.
Although genetic heterogeneity has been shown for PCG, homogeneity in phenotype as well as genotype (E387K) has been reported in the Slovakian Romany people, and common haplotypes (G61E, D374N, R469W) have been associated with the Saudi Arabian population.11 12 Inbreeding and consanguinity are prevalent in these communities, as in India. Thus, it is of interest to determine which haplotypes are present in the Indian patients. Against this background, we now describe the results of screening for the known mutations in a cohort of 138 pedigrees of 146 patients, by using PCR-RFLPbased simple diagnostic methods.
| Materials and Methods |
|---|
|
|
|---|
Mutation Screening of CYP1B1
Genomic DNA was extracted from the peripheral leukocytes of all patients with PCG and control subjects. The translated region (1.6 kb) spanning exons II and III of the gene for cytochrome P4501B1 (CYP1B1)21 from patients and control subjects were amplified by using three sets of primers, as described earlier.18
PCR-Restriction Fragment Length Polymorphism and Direct Sequencing
The PCR-RFLP methods described earlier18 were followed, along with an Hin6I (MBI Fermentas, Vilnius, Lithuania) restriction enzymebased RFLP for 1514C
T (R390C) mutation. DNA samples from 70 voluntary donors, without a history of systemic and eye disorders, were used in control experiments. PCR-RFLPpositive samples were sequenced (for reconfirming the respective mutations) using an automated DNA sequencer (Big Dye Terminator cycle sequencing, ABI Prism 3700; Applied Biosystems, Foster City, CA).
| Results |
|---|
|
|
|---|
A substitution at base pair position 1449, leading to the amino acid (aa) change arginine to histidine at position 368 (R368H), whereas the second mutation was a novel sequence variation, a C
T substitution at base pair 1514 (Fig. 1A) , causing the change arginine to cysteine at position 390 (R390C). The father (Fig. 1B , 1II.1) in the same family, also affected by PCG, was homozygous for the novel mutation 1514C
T. The grandparents (I.1 and I.2) as well as the unaffected sibling (III.1) were heterozygous (carriers) for the mutation. Both mutations, R368H and R390C were found in exon III and resulted in loss of restriction sites TaaI and Hin6I respectively. The cosegregation of mutations in the family was ascertained by using the PCR-RFLP method. In this pedigree, the grandparents (I.1 and I.2) had a consanguineous marriage, whereas the parents (II.1 and II.2) were nonconsanguineous (Fig. IB).
|
A, 923C
T, 959G
A, 1449G
A, and 1514C
T. Of the 146 patients in 138 pedigrees, 45 patients in 37 pedigrees were positive for one of these six mutations. All the PCR-RFLPpositive samples were subsequently sequenced to confirm the mutation. More than 30% of the patients were carriers of the respective mutation, as revealed later by sequencing. Among the six mutations, R368H was the predominant PCG allele in this cohort, and 17.8% of the patients were found to be either homozygous or heterozygous for this mutation. | Discussion |
|---|
|
|
|---|
The homogeneityheterogeneity pattern varies with ethnic groups, as does the phenotypic uniformity of the condition. Whereas the Slovak Romany cases showed allelic homogeneity and phenotypic uniformity,11 other population studies reported high clinical and allelic heterogeneity. Among these groups, higher homogeneity was present in the Saudi Arabian population (with 72% having the G61E allele and 12% the R469W allele12 ), whereas other populations demonstrated increased genetic heterogeneity. The homogeneity reflects the higher rate of inbreeding in this population. Our PCR-RFLP screening, for six distinct alleles, in a cohort of 146 patients in 138 pedigrees showed a frequency of 16.21% for allele R368H.
This mutation has so far been reported in only a very few PCG families from Saudi Arabia and Brazil and at a very low frequency.12 20 In the present study, however, based on the mutation screening, we found it to be a predominant allele associated with PCG in India. This is the highest reported frequency of this mutation of all ethnic backgrounds studied so far, indicating that the frequency of the mutation could vary based on the ethnic origin as well as geographical location. Sequence analysis of the remaining families negative for these six mutations should to be performed to determine whether there are any other predominant alleles in Indian patients with PCG. The possibility of locus heterogeneity in Indian patients with PCG also should be explored further.
Ethnically matched population screening of 140 chromosomes for these six mutant alleles showed 6.4% and 0.7% carriers for E229K and R368H, respectively. The present data are unlikely to be due to a possible founder effect for the predominant R368H allele, because patients were from ethnically as well as geographically diverse groups in India. Also, these mutations are equally distributed in both consanguineous and nonconsanguineous pedigrees (Table 1) . Of the total families recruited, 51.5% belonged to the nonconsanguineous group. Sporadic cases accounted for 80%, and bilateral 88%. Males accounted for 57% of the affected individuals.
|
Consanguineous marriages and marriages within a distinctive caste or community increase the predisposition and incidence of recessively inherited and multifactorial diseases in the population. It is important to know the carrier status of unaffected members in the families with a positive history to identify the at-risk individuals in such families. Earlier studies have reported that 30% to 35% of blind children in India show a history of hereditary disorder.22 In the higher socioeconomic levels of developed countries, 22% to 55% of children with genetic disease show an autosomal recessive mode of inheritance.23 Hence, development of techniques such as PCR-RFLP, the amplification refractory mutation system (ARMS)-PCR, allele-specific oligonucleotide (ASO) blot analysis, and other methods are important for segregation analysis in families with a positive history and for possible prenatal diagnosis and genetic counseling. Moreover, because this disease carries high and life-long morbidity, development of strategies that are noninvasive, rapid, and cost-effective are very useful in screening populations with a high incidence of this disease. This could in turn help in identifying individuals at risk and also assist in preventing unwanted visual loss in the afflicted families. An earlier study on thalassemia major in a Sardinian population showed that genetic screening and counseling helped to reduce the incidence from 1 in 250 live births to 1 in 4000.24
Similarly, the molecular diagnostic methods used in the current study could be used as an added clinical tool in decreasing the incidence of the devastating binding disorder PCG in the afflicted families.
Moreover, our clinical experience in PCG has shown that early diagnosis, along with prompt medical and surgical interventions, result in better prognosis.25 We thus see the use of the PCR-RFLP molecular diagnosis described in this study as a tool to identify the disease early and to initiate appropriate and prompt treatments, especially in patients with late manifestation and positive family history. Based on this study, we suggest that PCG mutation screening in India should be performed based on the prevalence of the mutation.
Our study shows that 31% of the patients studied had one of the six mutations that we sought in the screening. Whereas only direct screening or methods such as denaturing HPLC can identify all mutations in CYP1B1, R368H appears to be the predominant mutant allele causing PCG in the population studied herein. Given this lead, we believe that screening for this mutation should be given priority, and subsequently the other reported mutations should be screened for in the order of prevalence. Thus, the data derived from this study highlight the use of a rapid screening system for mutations that could assist the medical community in the management of this devastating condition
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication September 14, 2002; revised November 22, 2002; accepted January 2, 2003.
Disclosure: A.B.M. Reddy, None; S.G. Panicker, None; A.K. Mandal, None; S.E. Hasnain, None; D. Balasubramanian, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Dorairajan Balasubramanian, Brien Holden Eye Research Centre, Hyderabad Eye Research Foundation, L. V. Prasad Eye Institute, L. V. Prasad Marg, Banjara Hills, Hyderabad 500034, Andhra Pradesh, India; dbala{at}lvpeye.stph.net.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Chen, D. Jiang, L. Yu, B. Katz, K. Zhang, B. Wan, and X. Sun CYP1B1 and MYOC Mutations in 116 Chinese Patients With Primary Congenital Glaucoma Arch Ophthalmol, October 1, 2008; 126(10): 1443 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bidinost, N. Hernandez, D. P. Edward, A. Al-Rajhi, R. A. Lewis, J. R. Lupski, D. W. Stockton, and B. A. Bejjani Of mice and men: tyrosinase modification of congenital glaucoma in mice but not in humans. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1486 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chakrabarti, K. Kaur, I. Kaur, A. K. Mandal, R. S. Parikh, R. Thomas, and P. P. Majumder Globally, CYP1B1 Mutations in Primary Congenital Glaucoma Are Strongly Structured by Geographic and Haplotype Backgrounds Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 43 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Panicker, A. K. Mandal, A. B. M. Reddy, V. K. Gothwal, and S. E. Hasnain Correlations of Genotype with Phenotype in Indian Patients with Primary Congenital Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2004; 45(4): 1149 - 1156. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |